Leveraging FSS Sales as Strategic Evidence

Bottom Line

Recognizing federal sales patterns as real-world evidence gives manufacturers the clinical validation private payers can use to justify coverage decisions.

Pharmaceutical and medical device manufacturers that treat the execution of their Federal Supply Schedule (FSS) as the finish line of a sales journey rather than the starting point of a much more valuable evidence cycle miss a critical opportunity. When a manufacturer views its FSS sales solely through a transactional lens, the true economic and clinical utility of the asset is often obscured. Because the Department of Veterans Affairs (VA) is a large, highly integrated healthcare system that manages a substantial portion of many patients' long-term health needs, its doctors possess a unique clinical independence. This freedom allows for a rigorous vetting of technology based on real-world value. By capturing the unique, independent protocol evolutions that occur within the VA network, organizations can expand their commercial relevance.

The core vulnerability for manufacturers post-launch is evidence stagnation. During the initial commercialization phase, messaging is predictably tethered to controlled clinical trial data. While essential for regulatory approval and early market entry, this static data set rapidly loses its competitive edge as a product matures. In the commercial sector, real-world data collection is frequently fragmented by shifting patient populations, varied payer criteria, and discontinuous care journeys. Consequently, messaging can remain anchored to historical data instead of leveraging field performance to demonstrate how a therapy performs when deployed at scale within a complex, multi-morbid population. Capturing this data is what ultimately bridges a product’s theoretical value proposition to the practical needs of value-based purchasers.

Operating as the nation’s largest integrated healthcare delivery system, the VA functions under a unique operational paradigm of longitudinal care management and clinical autonomy. Because patients typically remain within the system for decades, clinician focus naturally shifts to the long-term total cost of care. VA clinicians have the ability to champion local protocol shifts and utilization pathways that, if proven efficient, can drive regional or national changes. When a novel technology or therapy is introduced into this environment, the VA’s internal review mechanisms optimize utilization pathways to identify distinct patient sub-populations that derive the highest benefit and adjust care protocols to maximize system-wide outcomes. Since the VA captures every clinical encounter, prescription, and laboratory result within a unified electronic health record, the VA generates a depth of longitudinal real-world data that is difficult to replicate in fragmented commercial care settings, providing meaningful evidence of how a product performs across a complex, multi-morbid population.

The strategic inflection point occurs when a manufacturer recognizes the VA sales pattern as an opportunity to highlight real-world proof of value in the commercial market to justify coverage decisions. When the VA independently elevates product utilization or alters its internal usage to favor a specific technology, it signals validated long-term clinical value within a system that rigorously weighs both outcomes and acquisition cost. This real-world utilization pattern provides private payers with a proxy for how a product performs in a highly scrutinized and cost-conscious care model.

Market Segment	Decision-Making Horizon	Primary Data Dependency
Commercial Payer	Short-term (1–3 years due to member churn)	Actuarial risk, claims, clinical trial data
Department of Veterans Affairs	Long-term (Decade-plus longitudinal care)	Real-world outcomes, systemic protocol evolution

Treating the VA as a siloed volume play leaves substantial strategic capital on the table. By auditing the VA footprint not solely for sales revenue, but also for its longitudinal clinical data and utilization patterns across complex patient populations, manufacturers gain the raw material required to understand the opportunity for differentiated use in the commercial market for on-label use in optimal sub-populations.